The DOI matches its Crossref record.
Iron Chelators as Anti-Neoplastic Agents: Current Developments and Promise of the PIH Class of Chelators
Abstract
The chelator currently used to treat iron (Fe) overload disease, desferrioxamine (DFO), has shown anti-proliferative activity against leukemia and neuroblastoma cells in vitro, in vivo and in clinical trials. Collectively, these studies suggest that Fe-deprivation may be a useful anti-cancer strategy. However, the efficacy of DFO is severely limited due to its poor ability to permeate cell membranes and bind intracellular Fe pools. These limitations have encouraged the development of other Fe chelators that are far more effective than DFO. One group of ligands that have been extensively investigated are those of the pyridoxal isonicotinoyl hydrazone (PIH) class. In this review the marked anti-proliferative effects of the PIH analogs are discussed with reference to their mechanisms of action and structure-activity relationships. In particular, we discuss the activity of a novel group of ligands that are "hybrid" chelators derived from our most effective PIH analogs and thiosemicarbazones. The anti-tumor activity of the PIH analogs and other chelators such as tachpyridine, O-trensox and the desferrithiocin analogs have been well characterized in vitro. However, further studies in animals are critical to evaluate their selective anti-tumor activity and potential as therapeutic agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, pyridoxal isonicotinyl hydrazone (PIH) [1672,1715-1720] is a promising molecule (also proposed in anti-cancer therapy), although it is hydrolysed both in vivo and in vitro [1721].”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1719]
Citations
Cites
Still being checked.
Cited by
Redox- and non-redox-metal-induced formation of free radicals and their role in human disease
Valko, M., Jomova, K., Rhodes, C. J., Kuča, K., & Musílek, K. (2016) · Archives of Toxicology · doi:10.1007/s00204-015-1579-5 · Cited by 1,022
Antitumour metal compounds: more than theme and variations
Jakupec, M. A., Galanski, M. S., Arion, V. B., Hartinger, C. G., & Keppler, B. K. (2008) · Dalton Transactions · doi:10.1039/b712656p · Cited by 850
Microbial siderophores and their potential applications: a review
Saha, M., Sarkar, S., Sarkar, B., Sharma, B. K., Bhattacharjee, S., & Tribedi, P. (2016) · Environmental Science and Pollution Research · doi:10.1007/s11356-015-4294-0 · Cited by 819
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Kalinowski, D. S., & Richardson, D. R. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.2 · Cited by 721
Self-citationKell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Metadata
- Authors
- Lovejoy, D., & Richardson, D.
- Affiliations
- Children's Cancer Institute Australia (AU)
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-06-01
- Volume
- 10
- Issue
- 12
- Pages
- 1035-1049
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2002176182
- Cited by
- 98
- References
- 0
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2022: 6 · 2021: 4 · 2020: 4 · 2019: 3 · 2018: 1 · 2017: 1 · 2016: 4 · 2015: 4 · 2014: 5 · 2013: 5 · 2012: 4
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- iron chelators, pyridoxal isonicotinoyl hydrazone, deferoxamine, iron starvation, anticancer agents, antiproliferative activity, leukemia, neuroblastoma, thiosemicarbazones, structure-activity relationship, iron overload
- MeSH terms
- Animals, Antineoplastic Agents, Deferoxamine, Humans, Hydrazones, Iron, Iron Chelating Agents, Neoplasms, Structure-Activity Relationship
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Iron Chelators as Anti-Neoplastic Agents: Current Developments and Promise of the PIH Class of Chelators. https://app.cochat.ai/papers/10.2174/0929867033457557
- The paper
- Lovejoy, D., & Richardson, D. (2003). Iron Chelators as Anti-Neoplastic Agents: Current Developments and Promise of the PIH Class of Chelators. Current Medicinal Chemistry. https://doi.org/10.2174/0929867033457557
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.